Literature DB >> 24077512

Fluorescence in-situ hybridization and dermoscopy in the assessment of controversial melanocytic tumors.

Giovanni Ponti1, Cristel Ruini, Daniela Massi, Giovanni Pellacani, Aldo Tomasi, Milena Paglierani, Pietro Loschi, Stefania Seidenari.   

Abstract

Although the 'gold standard' for melanoma diagnosis remains histopathological analysis, presently dermoscopists play a significant role in the diagnostic process. However, even a combined approach may not allow a clear-cut judgment on equivocal melanocytic lesions. Fluorescence in-situ hybridization (FISH) can offer assistance in the evaluation of chromosome abnormalities associated with malignancies, and its role is emerging in melanoma diagnosis. The aim of this study was to evaluate the diagnostic role of the FISH in the assessment of controversial lesions, defined as those lesions showing discrepancies between dermatoscopic and histological evaluations. Twenty clinically and histologically ambiguous melanocytic lesions were selected. After the first histopathologic diagnosis, a second pathologist examined the specimens in a blinded review for a second opinion and to identify the most suitable areas to hybridize using probes specific to RREB1, MYB, and CCND1 genes and the centromere of chromosome 6. The first histopathological evaluation led to the diagnosis of melanoma in seven cases, whereas the second identified eight cases of malignant melanoma and was in agreement with the first in 65% of cases and with dermoscopy in 40% of cases. Cytogenetic abnormalities detected by FISH are markers of malignancy that can be useful in the characterization of difficult-to-diagnose melanocytic tumors, when the dermatologist and the pathologist have a different opinions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24077512     DOI: 10.1097/CMR.0000000000000020

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  1 in total

1.  Amelanotic metastatic gastric malignant melanoma: a case report.

Authors:  Min Zhu; Da-Ya Zhang; Guan-Jun Zhang; Zhan-Bo Wang; Ming-Yang Lid
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.